natgillin/translations-raw huggingface dataset:
(-0.3 for Metavir and -1.2 for Ishak) and stable (-0.1 for Metavir and -0.2 for Ishak) among non-responders. 
Ta upad je bil statistično značilen pri bolnikih, ki so se odzvali na zdravljenje (-0,3 pri oceni po Metavirju in -1,2 pri oceni po Ishaku) in stabilen (-0,1 pri oceni po Metavirju in -0,2 pri oceni po Ishaku) pri tistih, ki se niso odzvali na zdravljenje.
Adverse reactions reported with a > 10 % incidence in adult patients treated with Rebetol capsules in combination with interferon alfa-2b or pegylated interferon alfa-2b for one year have also been reported in children and adolescents. 
O neželenih učinkih, poročanih s pojavnostjo > 10 % pri odraslih bolnikih, ki so se eno leto zdravili z zdravilom Rebetol kapsule v kombinaciji z interferonom alfa-2b ali pegiliranim interferonom alfa-2b, so poročali tudi pri otrocih in mladostnikih.
Dose modification for adverse reactions 
Prilagoditev odmerka v primeru neželenih učinkov
Genotype 1* By Week 4*** (n= 950) HCV-RNA negative 
Do 4. tedna*** (n = 950) Negativen izvid testa na HCV-RNA
This medicinein combination with peginterferon alfa-2b or interferon alfa-2b may also cause: dark, cloudy or abnormally coloured urine, difficulty breathing, changes in the way your heart beats, chest pain, pain down left arm, jaw pain, loss of consciousness, loss of use, drooping or loss of power of facial muscles, loss of feeling sensation, loss of vision. 
To zdravilo v kombinaciji s peginterferonom alfa-2b ali interferonom alfa-2b lahko povzroči tudi: temen, moten ali nenormalno obarvan urin, težave z dihanjem, spremembe srčnega utripa, bolečine v prsih, bolečine navzdol po levi roki, bolečine v čeljustih, izgubo zavesti, nezmožnost premikanja, povešanje ali izgubo moči obraznih mišic, izgubo občutka za dotik, izgubo vida.
Weight loss and growth inhibition were very common during the treatment (at the end of treatment, mean decrease from baseline in weight and in height percentiles were of 15 percentiles and 8 percentiles, respectively) and growth velocity was inhibited (< 3 
Izguba telesne mase in zastoj rasti sta bila zelo pogosta med zdravljenjem (ob koncu zdravljenja je znašalo povprečno zmanjšanje telesne mase 15 percentilov, višine pa 8 percentilov glede na izhodiščno vrednost) in tudi njihova hitrost rasti je bila zmanjšana (pri 70 % bolnikov se je upočasnila za do 3 percentile).
Table 14 Sustained virological response in previously untreated children and adolescents Rebetol 15 mg/kg/day interferon alfa-2b 3 MIU/m2 3 times a week 
Preglednica 14 Trajni virološki odziv pri predhodno nezdravljenih otrocih in mladostnikih Zdravilo Rebetol 15 mg/kg na dan interferon alfa-2b 3 mio i.e./m2 3-krat na teden
In the HIV-positive population receiving an NRTI regimen, physicians should carefully monitor markers of mitochondrial toxicity and lactic acidosis when Rebetol is administered. 
Pri bolnikih, pozitivnih na HIV, ki se zdravijo po shemi NRTI, mora zdravnik pri sočasnem zdravljenju z zdravilom Rebetol skrbno spremljati pokazatelje mitohondrijske toksičnosti in laktacidoze.
Table 8 Virologic Response at End of Treatment, Sustained Virologic Response and Relapse by HCV Genotype and Viral Load* Rebetol 800-1,400 mg/day plus peginterferon alfa-2b 1.5 g/kg once weekly End of Treatment Response 
Preglednica 8 Virološki odziv ob koncu zdravljenja, trajni virološki odziv in ponovitev bolezni po HCV genotipih in virusni obremenitvi* Zdravilo Rebetol v odmerku 800 do 1.400 mg na dan plus peginterferon alfa-2b v odmerku 1,5 g/kg enkrat na teden odziv ob koncu zdravljenja trajni virološki odziv ponovitev bolezni
Twelve out of 492 sustained responders and only 3 out of 366 sustained responders relapsed, respectively, in the studies. 
V študijah se je bolezen ponovila pri dvanajstih od 492 bolnikov s trajnim virološkim odzivom iz prve skupine in le pri 3 od 366 bolnikov s trajnim virološkim odzivom iz druge skupine.
Reminder: Please read the “Do not take” section of the Package Leaflet for the other medicines used in combination with this medicine. 
Opozorilo: Prosimo, preberite poglavje "Ne jemljite" v navodilih za uporabo za druga zdravila, uporabljena v kombinaciji s tem zdravilom.
2 capsules in the morning and 2 capsules in the evening See adult dose 
2 kapsuli zjutraj in 2 kapsuli zvečer
Sustained Virologic Response (SVR) is defined as undetectable HCV-RNA at 24 weeks post-treatment (Table 12). 
Trajni virološki odziv (SVR) pa je bil opredeljen kot nezaznavna vrednost HCV-RNA 24 tednov po zdravljenju (preglednica 12).
The use of Rebetol in combination treatment with peginterferon alfa-2b or interferon alfa-2b was evaluated in a number of clinical trials. 
Uporabo zdravila Rebetol v kombinirani terapiji s peginterferonom alfa-2b ali interferonom alfa-2b so ovrednotili v številnih kliničnih preskušanjih.
Please read the “Possible side effects” section of the Package Leaflet for the other medicines used in combination with Rebetol. 
Prosimo, preberite poglavje "Možni neželeni učinki" v navodilih za uporabo za druga zdravila, uporabljena v kombinaciji z zdravilom Rebetol.
Severe adverse reactions were reported in 7 % (8/107) of all subjects and included injection site pain (1 %), pain in extremity (1 %), headache (1 %), neutropenia (1 %), and pyrexia (4 %). 
O hudih neželenih učinkih so poročali pri 7 % (8/107) vseh preiskovancih in mednje so sodili bolečina na mestu injiciranja (1 %), bolečina v udih (1 %), glavobol (1 %), nevtropenija (1 %) in zvišana telesna temperatura (4 %).
A large randomized trial compared the safety and efficacy of treatment for 48 weeks with two peginterferon alfa-2b/Rebetol regimens [peginterferon alfa-2b 1.5 µg/kg and 1 µg/kg subcutaneously once weekly both in combination with Rebetol 800 to 1,400 mg p.o. daily (in two divided doses)] and peginterferon alfa-2a 180 µg subcutaneously once weekly with ribavirin 1,000 to 1,200 mg p.o. daily (in two divided doses) in 3,070 treatment-naïve adults with chronic hepatitis C genotype 1. 
V velikem randomiziranem preskušanju so primerjali varnost in učinkovitost 48-tedenskega zdravljenja z dvema shemama peginterferona alfa-2b in zdravila Rebetol [peginterferon alfa-2b v odmerku 1,5 µg/kg in 1 µg/kg subkutano enkrat na teden, oboje v kombinaciji z zdravilom Rebetol 800 do 1.400 mg peroralno na dan (v dveh deljenih odmerkih)] in zdravljenja s peginterferonom alfa-2a 180 µg enkrat na teden subkutano z ribavirinom od 1.000 do 1.200 mg peroralno na dan (v dveh deljenih odmerkih) pri 3.070 odraslih s kroničnim hepatitisom C genotipa 1, ki predhodno niso bili zdravljeni.
oral solution 100 mL 
peroralna raztopina 100 ml
SVR after treatment of chronic HCV with non-pegylated interferon alfa-2b with Rebetol results in long-term clearance of the virus providing resolution of the hepatic infection and clinical 'cure' from chronic HCV. 
SVR po zdravljenju kronične okužbe s HCV z nepegiliranim interferonom alfa-2b in zdravilom Rebetol vodi do dolgoročne odstranitve virusa, s čimer zagotovimo odpravo jetrne okužbe in klinično "ozdravitev" kronične okužbe s HCV.
This product contains sucrose and sorbitol. 
To zdravilo vsebuje saharozo in sorbitol.
Rebetol in combination with peginterferon alfa-2b A five-year long-term, observational, follow-up study enrolled 94 paediatric chronic hepatitis C patients after treatment in a multicentre trial. 
Zdravilo Rebetol v kombinaciji s peginterferonom alfa-2b Petletna dolgoročna opazovalna spremljevalna študija je zajela 94 pediatričnih bolnikov s kroničnim hepatitisom C po zdravljenju v multicentričnem preskušanju.
Information on excipients 
Informacije o pomožnih snoveh
a: p value based on Cochran-Mantel Haenszel Chi square test. b: p value based on chi-square test. c: subjects < 75 kg received 100 µg/week peginterferon alfa-2b and subjects ≥ 75 kg received 150 µg/week peginterferon alfa-2b . 
Mio i.e. = milijonov mednarodnih enot a: vrednost p pri Cochran-Mantel Haenszelovem testu hi-kvadrat b: vrednost p pri testu hi-kvadrat c: preiskovanci s telesno maso < 75 kg so prejemali 100 µg peginterferona alfa-2b na teden, preiskovanci s telesno maso
Daily Rebetol dose 
Dnevni odmerek zdravila Rebetol
Depression, insomnia, emotional lability 
depresija, nespečnost, čustvena labilnost
However, response rates in this trial were shown to be dependent also on the dose of Rebetol administered in combination with peginterferon alfa-2b or interferon alfa-2b. 
Vendar pa je bil odziv v tej raziskavi odvisen tudi od odmerka zdravila Rebetol, ki so ga dajali v kombinaciji s peginterferonom alfa-2b ali interferonom alfa-2b.
During combination therapy for up to 48 weeks with interferon alfa-2b and Rebetol, growth inhibition was observed that resulted in reduced final adult height in some patients. 
V času kombinirane terapije z interferonom alfa-2b in zdravilom Rebetol, ki je trajala do 48 tednov, so opazili zastoj rasti, ki je pri nekaterih bolnikih povzročil manjšo končno telesno višino v odrasli dobi.
Due to the lack of data in these two multicentre trials for children with severe progression of the disease, and the potential for undesirable effects, the benefit/risk of the combination of Rebetol and interferon alfa-2b needs to be carefully considered in this population (see sections 4.1, 4.4 and 4.8). 
Zaradi pomanjkanja podatkov v teh dveh multičentričnih študijah pri otrocih s hudim napredovanjem bolezni in možnostjo pojava neželenih učinkov je potrebno pred uporabo kombinacije zdravila Rebetol in interferona alfa-2b v tej populaciji skrbno pretehtati razmerje med koristnostjo zdravljenja in tveganjem (glejte poglavja 4.1, 4.4 in 4.8).
Evening Dose 
jutranji odmerek večerni odmerek
A reduction in haemoglobin concentrations by > 4 g/dL was observed in 30 % of patients treated with Rebetol and peginterferon alfa-2b and 37 % of patients treated with Rebetol and interferon alfa-2b. 
Znižanje koncentracije hemoglobina za > 4 g/dl so opazili pri 30 % bolnikov, ki so prejemali zdravilo Rebetol in peginterferon alfa-2b, ter pri 37 % bolnikov, ki so prejemali zdravilo Rebetol in interferon alfa-2b.
The adverse reactions listed in this section are primarily derived from clinical trials and/or as adverse drug reactions from spontaneous reports when Rebetol was used in combination with interferon alfa-2b or peginterferon alfa-2b. 
Neželeni učinki, navedeni v tem poglavju, izvirajo v prvi vrsti iz kliničnih preskušanj in/ali spontano poročanih neželenih učinkov, ko je bilo zdravilo Rebetol uporabljeno v kombinaciji z interferonom alfa-2b ali peginterferonom alfa-2b.
In individual cases where the benefit of administering Rebetol concomitantly with azathioprine warrants the potential risk, it is recommended that close hematologic monitoring be done during concomitant azathioprine use to identify signs of myelotoxicity, at which time treatment with these medicines should be stopped (see section 4.4). 
V posameznih primerih, kjer je korist sočasnega zdravljenja z zdravilom Rebetol in azatioprinom večja kot možno tveganje, je med sočasnim zdravljenjem z azatioprinom priporočljivo skrbno spremljanje hematoloških parametrov, da se lahko ugotovijo znaki mielotoksičnosti.
Endocrine disorders Very common: 
Bolezni endokrinega sistema Zelo pogosti:
Limited safety data (N = 25) are available in co-infected patients with CD4+ cell counts < 200/µL (see section 4.4). 
Za sočasno okužene bolnike s številom celic CD4+ < 200/µl je na voljo malo podatkov o varnosti zdravila (n = 25) (glejte poglavje 4.4).
For patients receiving a 800 mg (< 65 kg)-1,000 mg (65-80 kg)-1,200 mg (81-105 kg) or 1,400 mg (> 105 kg) dose, 1 
Pri bolnikih, ki prejemajo odmerek 800 mg (< 65 kg) - 1.000 mg (65-80 kg) - 1.200 mg (81-105 kg) ali 1.400 mg (> 105 kg), naj bo prvo zmanjšanje odmerka zdravila Rebetol za 200 mg/dan (razen pri bolnikih, ki prejemajo 1.400 mg - pri njih odmerek zmanjšajte za 400 mg/dan).
Please refer to the corresponding SmPC of medicinal products that are used in combination with Rebetol for additional undesirable effects reported with these products. 
Prosimo, glejte ustrezne povzetke glavnih značilnosti zdravil, uporabljenih v kombinaciji z zdravilom Rebetol, za dodatne neželene učinke, poročane pri teh zdravilih.
In Study 1 (see section 5.1), decrease in absolute neutrophil count levels below 500 cells/mm was observed in 4 % (8/194) of patients and decrease in platelets below 50,000/mm 
V študiji 1 (glejte poglavje 5.1) so opazili zmanjšanje absolutnega števila nevtrofilcev pod 500 celic/mm
• Rebetol (1,000/1,200 mg/day) + interferon alfa-2b (3 MIU three times a week) (n = 505). 
• Rebetol (1.000/1.200 mg/dan) + interferon alfa-2b (3 mio i.e. trikrat na teden) (n = 505).
d: Rebetol dosing was 800 mg for patients < 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients > 75 kg. 
d: odmerek zdravila Rebetol je znašal 800 mg za bolnike s telesno maso < 60 kg, 1.000 mg za bolnike s telesno maso od 60
Pancytopenia: Rebetol can cause a decrease in your platelet and red and white blood cell count when used in combination with peginterferon. 
Pancitopenija: Zdravilo Rebetol lahko v kombinaciji s peginterferonom povzroči zmanjšanje števila krvnih ploščic (trombocitov) in rdečih ter belih krvnih celic.
Rebetol, by having an inhibitory effect on inosine monophosphate dehydrogenase, may interfere with azathioprine metabolism possibly leading to an accumulation of 6-methylthioinosine monophosphate (6-MTIMP), which has been associated with myelotoxicity in patients treated with azathioprine. 
Zaradi inhibitornega učinka na inozin-monofosfat-dehidrogenazo lahko zdravilo Rebetol vpliva na presnovo azatioprina, kar lahko privede do kopičenja 6-metiltioinozin monofosfata (6-MTIMP).
In a non-comparative trial, 2,293 patients with moderate to severe fibrosis who failed previous treatment with combination alpha interferon/ribavirin were retreated with peginterferon alfa-2b, 1.5 microgram/kg subcutaneously, once weekly, in combination with weight adjusted Rebetol. 
V neprimerjalnem preskušanju so skupaj 2.293 bolnikov z zmerno do hudo fibrozo, pri katerih je bilo predhodno zdravljenje s kombinacijo interferona alfa in ribavirina neuspešno, ponovno zdravili s peginterferonom alfa-2b v odmerku 1,5 mikrograma/kg enkrat na teden subkutano, v kombinaciji z zdravilom Rebetol v odmerku, odvisnem od bolnikove telesne mase.
In a separate trial, 224 patients with genotype 2 or 3 received peginterferon alfa-2b, 1.5 microgram/kg subcutaneously, once weekly, in combination with ribavirin 800 mg -1,400 mg p.o. for 6 months (based on body weight, only three patients weighing > 105 kg, received the 1,400 mg dose) (Table 8). 
V ločenem preskušanju je 224 bolnikov z genotipom 2 ali 3 prejemalo peginterferon alfa-2b v odmerku 1,5 mikrogramov/kg subkutano enkrat na teden, v kombinaciji z zdravilom Rebetol v odmerku od 800 mg do 1.400 mg peroralno, v času 6 mesecev (glede na telesno maso - 1.400 mg za bolnike s telesno maso > 105 kg; vključeni so bili le 3 bolniki) (preglednica 8).
Rebetol (1,000/1,200 mg) + interferon alfa-2b (3 MIU) 
zdravilo Rebetol (1.000/1.200 mg) + interferon alfa-2b (3 mio i.e.)
Please refer to the corresponding SmPC of medicinal products used in combination with Rebetol for discontinuation or dose modification recommendations. 
Prosimo, glejte ustrezne povzetke glavnih značilnosti zdravil, uporabljenih v kombinaciji z zdravilom Rebetol, za priporočila o prenehanju uporabe oziroma prilagoditvi odmerkov.
P1.5/R Rebetol (800 mg) + peginterferon alfa-2b (1.5 micrograms/kg) P0.5/R Rebetol (1,000/1,200 mg) + peginterferon alfa-2b (1.5 to 0.5 microgram/kg) I/R 
P1,5/R zdravilo Rebetol (800 mg) + peginterferon alfa-2b (1,5 mikrogramov/kg) P0,5/R zdravilo Rebetol (1.000/1.200 mg) + peginterferon alfa-2b (1,5 do 0,5 mikrogramov/kg) I/R
Most of the changes in laboratory values in the Rebetol/peginterferon alfa-2b clinical trial were mild or moderate. 
V kliničnem preskušanju z zdravilom Rebetol in peginterferonom alfa-2b so bile spremembe v laboratorijskih vrednostih večinoma blage ali zmerne.
Bacterial infection (including sepsis), fungal infection, influenza, respiratory tract infection, bronchitis, herpes simplex, sinusitis, otitis media, rhinitis, urinary tract infection 
bakterijska okužba (vključno s sepso), glivna okužba, gripa, okužba zgornjih dihal, bronhitis, herpes simpleks, sinuzitis, otitis media, rinitis, okužba sečil
- Teratogenicity: Significant teratogenic and/or embryocidal potential have been demonstrated for Rebetol in all animal species in which adequate studies have been conducted, occurring at doses as low as one twentieth of the recommended human dose (see section 5.3). 
- Teratogenost: Za zdravilo Rebetol je bil dokazan pomemben teratogeni in/ali embriocidni potencial pri vseh živalskih vrstah, pri katerih so bile opravljene ustrezne študije.
Please refer to the corresponding SmPC of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with Rebetol in combination with other medicinal products. 
Prosimo, glejte ustrezne povzetke glavnih značilnosti protiretrovirusnih zdravil, uporabljenih sočasno s terapijo za HCV, da bi se bolj zavedali in bi lahko obvladovali toksične učinke vsakega od teh zdravil ter potencialno prekrivanje njihovih toksičnih učinkov z zdravilom Rebetol v kombinaciji z drugimi zdravili.
Table 2 provides guidelines for dose modifications and discontinuation based on the patient's haemoglobin concentration and indirect bilirubin concentration. 
Preglednica 2 prikazuje smernice za prilagoditev odmerka in prenehanje zdravljenja na podlagi bolnikove koncentracije hemoglobina in koncentracije indirektnega bilirubina.
- Retreatment of relapse patients with Rebetol and interferon alfa-2b combination treatment Two trials examined the use of Rebetol and interferon alfa-2b combination treatment in relapse patients (C95-144 and I95-145); 345 chronic hepatitis patients who had relapsed after previous interferon treatment were treated for six months with a six month follow-up. 
V dveh preskušanjih so raziskovali uporabo kombinacije zdravila Rebetol in interferona alfa-2b pri bolnikih s ponovitvijo bolezni (C95-144 in I95-145); 345 bolnikov s kroničnim hepatitisom, pri katerih se je bolezen ponovila po predhodnem zdravljenju z interferonom, so zdravili šest mesecev, in jih nato spremljali še šest mesecev.
Table 11 Sustained virological response based on genotype after Rebetol in combination with peginterferon alfa-2b in HCV/HIV co-infected patients Study 1 
Preglednica 11 Trajni virološki odziv glede na genotip po prejemanju zdravila Rebetol v kombinaciji s peginterferonom alfa-2b pri bolnikih, sočasno okuženih s HCV in HIV
Bitherapy with peginterferon alfa-2b or interferon alfa-2b: 
Dvojno zdravljenje s peginterferonom alfa-2b ali interferonom alfa-2b:
Each hard capsule contains 200 mg of ribavirin. 
Ena trda kapsula vsebuje 200 mg ribavirina.
For use in patients with decompensated cirrhosis, see the corresponding SmPC of the medicinal products used in combination with Rebetol. 
Za uporabo pri bolnikih z dekompenzirano cirozo jeter glejte ustrezne povzetke glavnih značilnosti zdravil, uporabljenih v kombinaciji z zdravilom Rebetol.
In case of serious adverse reaction potentially related to medicinal products used in combination with Rebetol, please refer to the corresponding SmPC of these medicinal products as some combination regimens do not adhere to the Rebetol dose modification and/or discontinuation guidelines as described in Table 2. 
V primeru resnih neželenih učinkov, ki bi lahko bili povezani z zdravili, uporabljenimi v kombinaciji z zdravilom Rebetol, prosimo, glejte ustrezne povzetke glavnih značilnosti teh zdravil, ker za nekatere kombinirane sheme ne veljajo smernice za odmerjanje in/ali prenehanje uporabe zdravila Rebetol, opisane v preglednici 2.
Haematological abnormalities in HCV/HIV co-infected patients HCV/HIV co-infected patients receiving peginterferon alfa-2b/ribavirin treatment and cART may be at increased risk to develop haematological abnormalities (as neutropenia, thrombocytopenia and anaemia) compared to HCV mono-infected patients. 
Hematološke motnje pri bolnikih, sočasno okuženih s HCV in HIV Bolniki, ki so sočasno okuženi z virusom HCV in HIV ter se zdravijo s peginterferonom alfa-2b/ribavirinom in s terapijo cART, imajo lahko zvečano tveganje za nastanek hematoloških motenj (v obliki nevtropenije, trombocitopenije in anemije) v primerjavi s tistimi, ki so okuženi samo s HCV.
Rebetol contains the active substance ribavirin. 
Zdravilo Rebetol vsebuje zdravilno učinkovino ribavirin.
Genotype 1  600,000 IU/mL 
Genotip 1  600.000 i.e./ml vsi
Reminder: Please read the “Warnings and precautions” section of the Package Leaflet for the other medicines used in combination with Rebetol before you begin combination treatment. 
Opozorilo: Prosimo, preberite poglavje "Opozorila in previdnostni ukrepi" v navodilih za uporabo za druga zdravila, uporabljena v kombinaciji z zdravilom Rebetol, preden začnete s kombiniranim zdravljenjem.
A certain number of adverse reactions, generally attributed to interferon therapy but that have been reported in the context of hepatitis C therapy (in combination with Rebetol) are also listed for reference in Table 5. 
V preglednici 5 je za primerjavo podano tudi nekaj neželenih učinkov, ki so jih običajno pripisovali zdravljenju z interferonom, vendar so o njih poročali tudi med zdravljenjem hepatitisa C (v kombinaciji z zdravilom Rebetol).
In clinical trials with Rebetol used in combination with interferon alfa-2b, the maximum overdose reported was a total dose of 10 g of Rebetol (50 x 200 mg capsules) and 39 MIU of interferon alfa-2b (13 subcutaneous injections of 3 MIU each) taken in one day by a patient in an attempt at suicide. 
V kliničnih preskušanjih z zdravilom Rebetol v kombinaciji z interferonom alfa-2b je bilo največje preveliko odmerjanje skupni odmerek 10 g zdravila Rebetol (50 x 200 mg kapsul) in 39 mio i.e. interferona alfa-2b (13 subkutanih injekcij po 3 mio i.e. vsaka), ki ga je v enem dnevu vzel bolnik v poskusu samomora.
Tabulated list of adverse reactions for adults 
Seznam neželenih učinkov pri odraslih v preglednici
• Dental and periodontal disorders: Dental and gum disorders have been reported in patients receiving Rebetol in combination with (peg)interferon alfa-2b. 
• Zobne in obzobne bolezni: Pri bolnikih, ki so prejemali zdravilo Rebetol v kombinaciji s (peg)interferonom alfa-2b, so poročali o boleznih zob in dlesni.
• Rebetol (800 mg/day) + peginterferon alfa-2b (1.5 micrograms/kg/week) (n = 511). 
• Rebetol (800 mg/dan) + peginterferon alfa-2b (1,5 mikrogramov/kg na teden) (n = 511).
The population enrolled mainly consisted of children with mild to moderate hepatitis C. Due to the lack of data in children with severe progression of the disease, and the potential for undesirable effects, the benefit/risk of the combination of Rebetol and pegylated interferon alfa-2b needs to be carefully considered in this population (see sections 4.1, 4.4 and 4.8). 
Skupina bolnikov, vključenih v preskušanje, je bila sestavljena predvsem iz otrok z blagim do zmernim hepatitisom C. Zaradi pomanjkanja podatkov pri otrocih z močno napredovalo boleznijo in zaradi nevarnosti za pojav neželenih učinkov je treba pri tej skupini bolnikov skrbno pretehtati razmerje med tveganji in koristmi zdravljenja s kombinacijo zdravila Rebetol in pegiliranega interferona alfa-2b (glejte poglavja 4.1, 4.4 in 4.8).
No interaction studies have been conducted with Rebetol and other medicinal products, except for peginterferon alfa-2b, interferon alfa-2b and antacids. 
Ni bilo opravljenih nobenih študij medsebojnega delovanja zdravila Rebetol z drugimi zdravili, razen za peginterferon alfa-2b, interferon alfa-2b in antacide.